Invention Grant
- Patent Title: RNAi modulation of SCAP and therapeutic uses thereof
-
Application No.: US13080334Application Date: 2011-04-05
-
Publication No.: US08383805B2Publication Date: 2013-02-26
- Inventor: Juergen Soutschek , Pamela Tan , Jay D. Horton , Michael S. Brown , Joseph L. Goldstein , Young-Ah Moon
- Applicant: Juergen Soutschek , Pamela Tan , Jay D. Horton , Michael S. Brown , Joseph L. Goldstein , Young-Ah Moon
- Applicant Address: US MA Cambridge US TX Austin
- Assignee: Alnylam Pharmaceuticals, Inc.,Board of Regents, The University of Texas System
- Current Assignee: Alnylam Pharmaceuticals, Inc.,Board of Regents, The University of Texas System
- Current Assignee Address: US MA Cambridge US TX Austin
- Agency: Fulbright & Jaworski L.L.P.
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C07H21/02 ; C12N15/63 ; C12N15/85
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
Public/Granted literature
- US20110184047A1 RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF Public/Granted day:2011-07-28
Information query
